The study investigates how the disruption of the p53 gene affects the response of human colon cancer cells to various therapeutic agents. p53 is a tumor suppressor gene that plays a critical role in cell cycle regulation and apoptosis. The researchers used targeted homologous recombination to create isogenic cell lines with either p53 or p21 disrupted. They found that p53 deficiency significantly altered the response to different drugs. DNA-damaging agents like adriamycin caused more apoptosis in p53-deficient cells due to the failure to induce p21, a cyclin-dependent kinase inhibitor. In contrast, p53-deficient cells were resistant to 5-fluorouracil (5-FU), a common chemotherapy drug for colorectal cancer. This resistance was independent of p21 and was linked to RNA metabolism rather than DNA metabolism. These findings suggest that p53 plays a crucial role in determining drug sensitivity, with different drugs having distinct dependencies on p53. The study also showed that p53-deficient cells were less sensitive to 5-FU in both in vitro and in vivo models. The resistance to 5-FU was not due to p21 but rather to changes in RNA metabolism. The results indicate that p53 is involved in both cell cycle checkpoints and apoptosis, and its disruption can lead to different therapeutic outcomes depending on the drug. The study highlights the importance of p53 in cancer therapy and suggests that patients with p53 mutations may respond differently to certain drugs. The findings have implications for personalized cancer treatment, as they show that genetic alterations can significantly influence drug responses. The research also emphasizes the need for further investigation into the molecular mechanisms of drug action, particularly in relation to RNA metabolism.The study investigates how the disruption of the p53 gene affects the response of human colon cancer cells to various therapeutic agents. p53 is a tumor suppressor gene that plays a critical role in cell cycle regulation and apoptosis. The researchers used targeted homologous recombination to create isogenic cell lines with either p53 or p21 disrupted. They found that p53 deficiency significantly altered the response to different drugs. DNA-damaging agents like adriamycin caused more apoptosis in p53-deficient cells due to the failure to induce p21, a cyclin-dependent kinase inhibitor. In contrast, p53-deficient cells were resistant to 5-fluorouracil (5-FU), a common chemotherapy drug for colorectal cancer. This resistance was independent of p21 and was linked to RNA metabolism rather than DNA metabolism. These findings suggest that p53 plays a crucial role in determining drug sensitivity, with different drugs having distinct dependencies on p53. The study also showed that p53-deficient cells were less sensitive to 5-FU in both in vitro and in vivo models. The resistance to 5-FU was not due to p21 but rather to changes in RNA metabolism. The results indicate that p53 is involved in both cell cycle checkpoints and apoptosis, and its disruption can lead to different therapeutic outcomes depending on the drug. The study highlights the importance of p53 in cancer therapy and suggests that patients with p53 mutations may respond differently to certain drugs. The findings have implications for personalized cancer treatment, as they show that genetic alterations can significantly influence drug responses. The research also emphasizes the need for further investigation into the molecular mechanisms of drug action, particularly in relation to RNA metabolism.